Compare DNOW & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | SLS |
|---|---|---|
| Founded | 1862 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2014 | 2007 |
| Metric | DNOW | SLS |
|---|---|---|
| Price | $15.30 | $11.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $18.75 | ★ $32.50 |
| AVG Volume (30 Days) | 1.8M | ★ 5.0M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $79.68 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $1.39 |
| 52 Week High | $17.26 | $15.88 |
| Indicator | DNOW | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 49.35 |
| Support Level | $12.60 | $10.82 |
| Resistance Level | $16.49 | $15.77 |
| Average True Range (ATR) | 0.42 | 0.75 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 0.87 | 79.10 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.